Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines

Dermatologic Surgery

Volumn 36, Issue SUPPL. 4, 2010, Pages 2111-2118

  Brandt, Fredric ^a   O'Connell, Christopher ^a   Cazzaniga, Alex ^a   Waugh, Jacob M ^b  

^a Dermatology Research Institute LLC   (United States)

^b Revance Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; RT 001; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EYE IRRITATION; FEMALE; HUMAN; LATERAL CANTHAL LINE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; WRINKLE;

ADMINISTRATION, TOPICAL; ADULT; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; EYE; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SKIN AGING; TREATMENT OUTCOME;

EID: 78650155418     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01711.x     Document Type: Article

References (29)

1. Carruthers J, Carruthers J., Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21.
2. Â Cosmetic (onabotulinumtoxinA) for injection Prescribing Information. Allergan 2009.
3. Dysport™ for Injection (abobotulinumtoxinA) Prescribing Information. Medicis Aesthetics 2009.
4. ASAPS. Cosmetic Procedures in 2009. American Society for Aesthetic Plastic Surgery 2010; Available at: Accessed April 2010.
5. Keen M, Blitzer A, Aviv J, et al,. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg 1994; 94: 94-9.
6. Blitzer A, Binder W, Aviv J, et al,. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997; 123: 389-92.
7. Ellis D, Tan A., Cosmetic upper-facial rejuvenation with botulinum. J Otolaryngol 1997; 26: 92-6.
8. Fagien S., Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103: 701-13.
9. Lowe N, Lask G, Yamauchi P, Moore D., Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002; 47: 834-40.
10. Baumann L, Slezinger A, Vujevich J, et al,. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial. Dermatol Surg 2003; 508-15.
11. Guerrissi J., Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow's feet. Plast Reconstr Surg 2003; 112: 161-3S.
12. Levy J, Servant J, Jouve E., Botulinum toxin A: a 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study. J Cosmet Laser Ther 2004; 6: 16-20.
13. Lowe N, Ascher B, Heckmann M, et al,. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257-562.
14. Ascher B, Rzany B, Grover R., Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35: 1478-86.
15. Coté T, Mohan A, Polder J, et al,. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53: 407-15.
16. Pena M, Alam M, Yoo S., Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg 2007; 26: 29-33.
17. Matarasso S, Matarasso A., Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001; 108: 208-14. (Pubitemid 32587045)
18. Matarasso S., Decreased tear expression with an abnormal Schirmer's test following botulinum toxin type A for the treatment of lateral canthal rhytides. Dermatol Surg 2002; 28: 149-52.
19. Arat Y, Yen M., Effect of botulinum toxin type A on tear production after treatment of lateral canthal rhytids. Ophthal Plast Reconstr Surg 2007; 23: 22-4.
20. Racette B, Lopate G, Good L, et al,. Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology 2002; 59: 1445-7.
21. Rowe F, Noonan C., Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev 2009:CD006499.
22. Dutton J, Fowler A., Botulinum toxin in ophthalmology. Surv Ophthalmol 2007; 52: 13-31.
23. Sarifakioglu N, Sarifakioglu E., Evaluating the effects of ice application on the pain felt during botulinum toxin type-a injections: a prospective, randomized, single-blind controlled trial. Ann Plast Surg 2004; 53: 543-6.
24. Wollina U, Konrad H., Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol 2005; 6: 141-50.
25. Carruthers A, Carruthers J., Single-center, double-blind, randomized study to evaluate the efficacy of 4% lidocaine cream versus vehicle cream during botulinum toxin type A treatments. Dermatol Surg 2005; 31: 165-9.
26. Bates B., A Guide to Physical Examination and History Taking. 6th ed. Philadelphia: Lippincott; 1997.
27. Yen T, Driscoll C, Lalwani A., Significance of House-Brackmann facial nerve grading global score in the setting of differential facial nerve function. Otol Neurotol 2003; 24: 118-22.
28. Dykes P, Marks R., An evaluation of the irritancy potential of povidone iodine solutions: comparison of subjective and objective assessment techniques. Clin Exp Dermatol 1992; 17: 246-9.
29. Food and Drug Administration. Guidance for Industry. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. US Department of Health and Human Services, Center for Drug Evaluation and Research; 1999, Rockville, MD.